Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Non-Small-Cell Lung Cancer|Ovarian Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TCD11379 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2014-10-01 |
2019-03-19 |
Treatments |
|
| TCD11270 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-10-01 |
2019-03-19 |
Treatments |
|
| TCD10620 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-02-01 |
2019-03-18 |
Treatments |
|
| TCD11089 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-12-01 |
2019-03-19 |
Treatments |
|
| TED10967 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-08-01 |
2019-03-19 |
Treatments |
|
| TCD11088 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-05-01 |
2019-03-19 |
Treatments |
|
| BEX6587 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-03-01 |
2019-03-19 |
Treatments |
|
| TCD6295 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-02-01 |
2019-03-19 |
Treatments |
|
| OPSALIN | P2 |
Completed |
Ovarian Cancer |
2014-07-01 |
2019-03-19 |
Treatments |
|
| OPSALIN | P2 |
Completed |
Ovarian Cancer |
2013-01-02 |
2022-03-13 |
Treatments |
|
| DISRUPT | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2012-10-02 |
2022-03-13 |
Treatments |
|
| DISRUPT | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2012-03-01 |
2019-03-19 |
||
| 2007-003592-39 | P3 |
Completed |
Sarcoma |
2013-04-17 |
2022-03-12 |
Treatments |
|
| EFC10145 | P3 |
Completed |
Sarcoma |
2013-04-01 |
2019-03-18 |
Treatments |